2 weeks Ago By ABMN Staff
Invesco Ltd. raised its holdings in Scholar Rock Holding Co. ( NASDAQ:SRRK – Free Report ) by 1,292.
8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 312,161 shares of the company’s stock after purchasing an additional 289,748 shares during the quarter. Invesco Ltd.
owned about 0.33% of Scholar Rock worth $13,492,000 as of its most recent filing with the SEC. A number of other institutional investors and hedge funds have also made changes to their positions in the business.
FMR LLC increased its position in Scholar Rock by 33.7% in the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock valued at $589,316,000 after acquiring an additional 3,439,215 shares during the period.
Vanguard Group Inc. increased its holdings in shares of Scholar Rock by 17.6% in the fourth quarter.
Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock valued at $205,013,000 after purchasing an additional 708,817 shares during the period. Norges Bank purchased a new stake in shares of Scholar Rock during the fourth quarter worth approximately $86,043,000.
Geode Capital Management LLC raised its stake in shares of Scholar Rock by 14.7% during the fourth quarter. Geode Capital Management LLC now owns 1,770,324 shares of the company’s stock worth $76,530,000 after purchasing an additional 227,299 shares during the last quarter.
Finally, Wellington Management Group LLP grew its position in Scholar Rock by 763.8% in the 4th quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company’s stock valued at $74,581,000 after buying an additional 1,525,845 shares during the last quarter.
91.08% of the stock is owned by hedge funds and other institutional investors. Scholar Rock Trading Down 3.
1 % Shares of SRRK stock opened at $29.81 on Tuesday. Scholar Rock Holding Co.
has a 1-year low of $6.76 and a 1-year high of $46.98.
The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.
88. The business’s fifty day moving average price is $33.11 and its 200 day moving average price is $35.
63. The firm has a market capitalization of $2.83 billion, a PE ratio of -12.
69 and a beta of 0.56. Wall Street Analyst Weigh In Get Our Latest Report on Scholar Rock Insider Transactions at Scholar Rock In other news, CFO Edward H.
Myles sold 142,292 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.
04. Following the sale, the chief financial officer now owns 111,345 shares of the company’s stock, valued at $3,966,108.90.
The trade was a 56.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink .
Also, insider Tracey Sacco sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.
00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at $2,373,490. The trade was a 8.
31 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders have sold a total of 250,231 shares of company stock valued at $9,056,086 in the last ninety days.
19.20% of the stock is currently owned by company insiders. About Scholar Rock ( Free Report ) Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. Further Reading Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter .
.
